TickerFacts.

NewcelX Ltd. (NCEL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$2.51M
Year ended 2025-12-31
2023-12-31: -$2.40M2024-12-31: -$1.65M2025-12-31: -$2.51M-$2.51M
2023-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$2.51Mn/m2026-04-29, From 2025-01-01
2024-12-31-$1.65Mn/m2026-04-29, From 2024-01-01
2023-12-31-$2.40Mn/a2026-04-29, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
NewcelX Ltd. (NCEL)2025-12-31-$2.51Mn/m
Decoy Therapeutics Inc. (DCOY)2025-12-31-$12.61Mn/m
Lantern Pharma Inc. (LTRN)2025-12-31-$17.96Mn/m
Turn Therapeutics Inc. (TTRX)2025-12-31-$5.81Mn/m
Imunon, Inc. (IMNN)2024-12-31-$18.89Mn/m
Traws Pharma, Inc. (TRAW)2025-12-31-$17.81Mn/m
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)2025-12-31-$11.63Mn/m
Longeveron Inc. (LGVN)2025-12-31-$22.49Mn/m
NRX Pharmaceuticals, Inc. (NRXP)2025-12-31-$16.15Mn/m

Compare NCEL, DCOY, LTRN, TTRX side by side · Screen every company in Pharmaceutical Preparations ↗